A study of the molecular mechanism of quercetin and dasatinib combination as senolytic in alleviating age‐related and kidney diseases. Issue 12 (21st October 2022)

• Record Type: Journal Article
• Authors: Alharbi, Khalid Saad; Afzal, Obaid; Altamimi, Abdulmalik Saleh Alfawaz; Almalki, Waleed Hassan; Kazmi, Imran; Al‐Abbasi, Fahad A.; Alzarea, Sami I.; Makeen, Hafiz A.; Albratty, Mohammed
• Is Part Of: Journal of food biochemistry. Volume 46:Issue 12(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-10-21
• Subjects: age‐related and kidney disease -- aging -- senolytic -- Wnt/β‐catenin -- α‐klotho; Food -- Analysis -- Periodicals; Food -- Composition -- Periodicals; Biochemistry -- Periodicals; 664.024
• DOI: 10.1111/jfbc.14471
• Languages: English
• ISSNs: 0145-8884

Abstract

Abstract: Aging is a significant risk factor for the majority of prevalent human illnesses. The chance of having severe chronic conditions grows dramatically with advancing age. Indeed, more than 90% of people over 65 get at least one chronic disease, including diabetes, heart disease, malignancy, memory loss, and kidney disease, whereas more than 70% have two or more of these ailments. Mouse and human aging lead to increased senescent cells and decreased klotho concentrations. Mice lacking the protein α‐klotho show faster aging, similar to human aging. α‐Klotho upregulation extends life and slows or suppresses the onset of many age‐related illnesses and kidney diseases. Like the consequences of α‐klotho deficiency, senescent cell accumulation is linked to tissue dysfunction in various organs and multiple age‐related kidney diseases. In addition, α‐klotho and cell senescence are negatively and presumably mechanistically linked. Earlier research has demonstrated that klotho exerts its protective effects in age‐related and kidney disease by interacting with Wnt ligands, serving as an endogenous antagonist of Wnt/β‐catenin signaling. In addition, decreasing senescent cell burden with senolytics, a class of drugs that remove senescent cells selectively and extend the life span of mice. In this work, we are studying the molecular mechanism of the combination of quercetin and dasatinib as senolytic in easing age‐related chronic renal illness by altering the level of klotho/Wnt/β‐catenin. Practical applications: There is an inverse relationship between the onset and the development of age‐related disorders and cellular senescence and Klotho. Earlier attempts to suppress transforming growth factor‐beta 1 (TGF‐β1) in kidney disease with anti‐TGF‐β1 antibodies were ineffective, and this should be kept in mind. Senolytic medications may benefit from targeting senescent cells, which enhances the protective factor α‐klotho. In addition, our study provides a unique, translationally feasible route for creating orally active small compounds to enhance α‐klotho, which may also be a valuable biomarker for age‐related kidney disease. Additionally, other aspects of aging can be affected by senolytics, such as limiting age‐related mitochondrial dysfunction, lowering inflammation and fibrosis, blunting reactive oxygen species (ROS) generation, decreasing deoxyribonucleic acid (DNA) damage, and reinforcing insulin sensitivity. Senolytic agents have been shown to increase adipose progenitor and cardiac progenitor cell activity in aging animals and animals with cellular senescence‐related diseases, such as heart, brain, and kidney disease. Abstract : Aging is a significant risk factor for the majority of prevalent human illnesses. α‐klotho upregulation extends life and slows the onset of many age‐related illnesses. We studied the mechanism of the combination of quercetin and dasatinib as senolytic. Senolytic drugs boost aging animals' adipose and cardiac progenitor cell activity.